Skip to content

Monitoring Telemedicine Platform in Patients With Anxiety Symptoms and Alcohol Use Disorder

REMOTE: Monitoring Telemedicine Platform in Patients With Anxiety Symptoms and Alcohol Use Disorder: Smartphone and Wearable Sensors

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03991650
Acronym
REMOTE
Enrollment
44
Registered
2019-06-19
Start date
2019-02-01
Completion date
2019-11-05
Last updated
2023-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Use Disorder, Anxiety Disorders, Depressive Disorder

Keywords

wearable, sensor, anxiety, monitoring, ehealth, Alcohol Use Disorder, depression

Brief summary

The objective of this study is to analyze the physiological patterns of two groups of patients, one control and one with anxiety disorder and alcoholic abuse disorder using sensor data from mobile devices and wearables. This data will be compared to the data presented by three clinical questionnaires: State-trait Anxiety Inventory (STAI), the Alcohol Use Disorders Identification Test (AUDIT), and the Beck's Depression Inventory (BDI-II) in order to determine the feasibility of remote collected data.

Detailed description

The objective of this study is to analyze the physiological patterns of two groups of patients, one control and one with anxiety disorder and alcoholic abuse disorder using sensor data from mobile devices and wearables. This data, collected by sensors, will be compared to the data presented by three clinical questionnaires: State-trait Anxiety Inventory (STAI), the Alcohol Use Disorders Identification Test (AUDIT), and the Beck's Depression Inventory (BDI-II) in order to determine the feasibility of using remote collected data in routine clinical practice. Furthermore, patient satisfaction with the app will be evaluated after the data collection phase. This is a unicentric, case-controlled, longitudinal, evaluational, national study with two groups, one control of healthy individuals without symptoms of anxiety or depression, and another experimental group in which participants fulfill the given selection criteria for the trial. There are a total of 60 participants split evenly between the two groups.

Interventions

BEHAVIORALMonitoring with a device

Participants will be monitored by an App.

Sponsors

Hospital Clinic of Barcelona
CollaboratorOTHER
European Institute of Innovation and Technology
CollaboratorUNKNOWN
humanITcare
Lead SponsorNETWORK

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* 18-65 years of age. * Alcohol use disorder (DSM 5) as main substance. * Anxiety (STAI \> percentile 33) and, if depressive symptoms, not clinically relevant as to accomplish DSM5 diagnostic criteria for mood disorders (major depressive disorder, bipolar disorder…). * Having a mobile phone compatible with Android. * Sign informed consent.

Exclusion criteria

* Mood disorder diagnoses (DSM5). * Cognitive deficits that prevent the participation. * Active intake of other substances (except for nicotine).

Design outcomes

Primary

MeasureTime frameDescription
Change in Self-reported Alcohol Abuse Symptoms assesed with the Alcohol Use Disorders Identification Test (AUDIT)One month, questionnaire taken 4 times (1/week)Taken through the application Ushine. Participants receive AUDIT scores ranging from 0-40. A score of 8 or more is associated with harmful or hazardous drinking, a score of 13 or more in women, and 15 or more in men, is likely to indicate alcohol dependence.
Sociability (number of incoming an outgoing calls and text messages)One monthThe number of incoming and outgoing calls and text messages will be monitored using the UShine app algorithm
Change in Self-reported Depression symptoms assessed with the Beck's Depression Inventory (BDI-II)One month, questionnaire taken 4 times (1/week)Taken through the application Ushine. Participants receive BDI-II scores ranging from 1-63, with a score of 0-13 indicating minimal depression, 14-19 indicating mild depression, 20-28 indicating moderate depression, and 29-63 indicating severe depression.
Change in Self-reported Anxiety symptoms assessed with the State-Trait Anxiety Inventory (STAI)One month, questionnaire taken 4 times (1/week)Taken through the application Ushine. Participants receive STAI scores ranging from 0-60, 0 being lowest amount of symptoms, and 60 being the greatest amount of symptoms, which are then transformed into percentiles according to age and sex.
Sleep patternOne monthMonitoring of circadian rhythm using a motion sensor Fitbit and cardiac activity sensor
REM sleep timeOne monthmonitoring of REM sleep patterns using a motion sensor Fitbit and cardiac activity sensor
Heart RateOne monthmonitoring of heart rate using Fitbit sensor
Step countOne monthMonitoring of daily step count using motion sensor FitBit
Distance travelledOne monthMonitoring of distance travelled using GPS phone
Mobile device usageOne monthMonitoring how often the patient's mobile device is used, determined by tracking the presence of a signal from their device

Secondary

MeasureTime frameDescription
Satisfaction with the applicationOne monthParticipants' satisfaction with the Ushine application will be scaled using the Post-Study Usability Questionnaire (PSSUQ). Scores range from 0-100, 0 being least satisfactory and 100 being the most satisfactory. The PSSUQ has 3 sub-scores representing system usefulness, information quality, and interface quality, also scaled from 0-100. In all score sets, 0 is considered the least satisfactory and 100 is considered the most satisfactory.
Usability of the mobile applicationOne monthEase of usability of the mobile applications by participants will be scaled using the System Usability Scale (SUS). Final scores range from 0-100. A score of 51 or under means the system has serious faults in usability, a score of 68 means the system usability is about average, and a score of 80.3 or higher means the system usability is considered appreciable.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026